Secukinumab treatment for ankylosing spondylitis and concomitant Huntington’s disease: real-world experience

dc.contributor.authorGökten, D. Bulut
dc.contributor.authorMercan, R.
dc.date.accessioned2024-10-29T17:43:42Z
dc.date.available2024-10-29T17:43:42Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstract[No abstract available]
dc.identifier.doi10.55563/clinexprheumatol/qm0e9d
dc.identifier.issn0392-856X
dc.identifier.issue3en_US
dc.identifier.pmid37877409
dc.identifier.scopus2-s2.0-85189375608
dc.identifier.scopusqualityQ2
dc.identifier.startpage767
dc.identifier.urihttps://doi.org/10.55563/clinexprheumatol/qm0e9d
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12572
dc.identifier.volume44
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherClinical and Experimental Rheumatology S.A.S.
dc.relation.ispartofClinical and Experimental Rheumatology
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleSecukinumab treatment for ankylosing spondylitis and concomitant Huntington’s disease: real-world experience
dc.typeLetter

Dosyalar